Approval · Notice of Compliance 38410 · 2026
JAMP ELAGOLIX: Notice of Compliance 38410
Issued October 6, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 38410
- Date
- October 6, 2026
- Company
- JAMP Pharma CorporationBoucherville, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Canadian reference product
- ORILISSA (AbbVie Corporation)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| JAMP ELAGOLIX | 02571048 | Approved |
| JAMP ELAGOLIX | 02571056 | Approved |
Medicinal ingredients
- ELAGOLIX SODIUM 150 MG per TAB
- ELAGOLIX SODIUM 200 MG per TAB